Scientific Publications

Search by Keyword(s)
Found 14 results

Filters: Author is Kung, AL  [Clear All Filters]

Search Results

  • Showing 1-14 of 14 Results
2014
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.Moore, NF, Azarova AM, Bhatnagar N., Ross KN, Drake LE, Frumm S., Liu QS, Christie AL, Sanda T., Chesler L., Kung AL, Gray NS, Stegmaier K., and George RE Oncotarget, 2014/08/19, (2014) Read More / View Supplemental Materials
Abstract
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.Knoechel, B., Roderick JE, Williamson KE, Zhu J., Lohr JG, Cotton MJ, Gillespie SM, Fernandez D., Ku M., Wang H., Piccioni F., Silver SJ, Jain M., Pearson D., Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A., et al. Nature genetics, 2014/03/02, (2014) Read More / View Supplemental Materials
Abstract
SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia.Puissant, A., Fenouille N., Alexe G., Pikman Y., Bassil CF, Mehta S., Du J., Kazi JU, Luciano F., Rönnstrand L., Kung AL, Aster J. C., Galinsky I., Stone RM, DeAngelo DJ, Hemann MT, and Stegmaier K. Cancer cell, 2014/02/10, Volume 25, Issue 2, p.226-42, (2014) Read More / View Supplemental Materials
Abstract
2013
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.Chapuy, B., McKeown MR, Lin CY, Monti S., Roemer MG, Qi J., Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E., Kung AL, Rodig SJ, Young RA, Shipp M. A., and Bradner JE Cancer cell, 2013/12/09, Volume 24, Issue 6, p.777-90, (2013) Read More / View Supplemental Materials
Abstract
Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation.Frumm, SM, Fan ZP, Ross KN, Duvall JR, Gupta S., VerPlank L., Suh BC, Holson E., Wagner FF, Smith WB, Paranal RM, Bassil CF, Qi J., Roti G., Kung AL, Bradner JE, Tolliday N., and Stegmaier K. Chemistry & biology, 2013/05/23, Volume 20, Issue 5, p.713-25, (2013) Read More / View Supplemental Materials
Abstract
High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma.Crompton, BD, Carlton AL, Thorner AR, Christie AL, Du J., Calicchio ML, Rivera MN, Fleming MD, Kohl NE, Kung AL, and Stegmaier K. Cancer research, 2013/05/01, Volume 73, Issue 9, p.2873-83, (2013) Read More / View Supplemental Materials
Abstract
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition.Puissant, A., Frumm SM, Alexe G., Bassil CF, Qi J., Chanthery YH, Nekritz EA, Zeid R., Gustafson WC, Greninger P., Garnett MJ, McDermott U., Benes CH, Kung AL, Weiss WA, Bradner JE, and Stegmaier K. Cancer discovery, 2013/03/01, Volume 3, Issue 3, p.308-323, (2013) Read More / View Supplemental Materials
Abstract
2012
Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma.Monti, S., Chapuy B., Takeyama K., Rodig SJ, Hao Y., Yeda KT, Inguilizian H., Mermel C., Currie T., Dogan A., Kutok JL, Beroukhim R., Neuberg D., Habermann TM, Getz G., Kung AL, Golub T. R., and Shipp M. A. Cancer cell, 2012/09/11, Volume 22, Issue 3, p.359-72, (2012) Read More / View Supplemental Materials
Abstract
Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency.Wei, G., Margolin AA, Haery L., Brown E., Cucolo L., Julian B., Shehata S., Kung AL, Beroukhim R., and Golub T. R. Cancer cell, 2012/04/17, Volume 21, Issue 4, p.547-62, (2012) Read More / View Supplemental Materials
Abstract
2009
Proteomic and genetic approaches identify Syk as an AML target.Hahn, CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K., Schinzel AC, Ross L., Galinsky I., Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M., Hahn WC, Carr SA, Golub T. R., Kung AL, and Stegmaier K. Cancer cell, 2009/10/06, Volume 16, Issue 4, p.281-94, (2009) Read More / View Supplemental Materials
Abstract
Identification of AML1-ETO modulators by chemical genomics.Corsello, SM, Roti G., Ross KN, Chow KT, Galinsky I., DeAngelo DJ, Stone RM, Kung AL, Golub T. R., and Stegmaier K. Blood, 2009/06/11, Volume 113, Issue 24, p.6193-205, (2009) Read More / View Supplemental Materials
Abstract
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.Du, J., Bernasconi P., Clauser KR, Mani D. R., Finn SP, Beroukhim R., Burns M., Julian B., Peng XP, Hieronymus H., Maglathlin RL, Lewis TA, Liau LM, Nghiemphu P., Mellinghoff IK, Louis DN, Loda M., Carr SA, Kung AL, and Golub T. R. Nature biotechnology, 2009/01/01, Volume 27, Issue 1, p.77-83, (2009) Read More / View Supplemental Materials
Abstract
2008
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.Hahn, CK, Ross KN, Warrington IM, Mazitschek R., Kanegai CM, Wright RD, Kung AL, Golub T. R., and Stegmaier K. Proceedings of the National Academy of Sciences of the United States of America, 2008/07/15, Volume 105, Issue 28, p.9751-6, (2008) Read More / View Supplemental Materials
Abstract
2007
Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.Stegmaier, K., Wong JS, Ross KN, Chow KT, Peck D., Wright RD, Lessnick SL, Kung AL, and Golub T. R. PLoS medicine, 2007/04/01, Volume 4, Issue 4, p.e122, (2007) Read More / View Supplemental Materials
Abstract
  • Showing 1-14 of 14 Results